Connect Biopharma's Rademikibart Phase 2 Asthma/COPD Trials Progress as Planned After Positive Interim Review

summarizeSummary

Connect Biopharma announced that an independent Data Monitoring Committee completed its interim review of Phase 2 trials for rademikibart in asthma and COPD, recommending no changes to sample size, indicating positive trial progression and safety.

check_boxKey Events

• Phase 2 Rademikibart Trials Progress

  The independent Data Monitoring Committee (DMC) completed its pre-specified interim analysis of efficacy for the Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart.

• No Sample Size Change Recommended

  The DMC recommended no change in sample size, indicating that enrollment will continue as planned, which is a positive signal for trial progression.

• Positive Safety Profile Noted

  Rademikibart continues to be well tolerated in the studies, with no treatment-related serious adverse events or discontinuations due to adverse events reported to date.

• Topline Data Expected Mid-2026

  The company remains on track to report topline results from both Seabreeze STAT studies in mid-2026, with plans to engage the FDA for a Phase 3 program.

auto_awesomeAnalysis

This 8-K reports a crucial interim milestone for Connect Biopharma's lead asset, rademikibart. The Data Monitoring Committee's decision to continue the Phase 2 Seabreeze STAT trials for asthma and COPD without recommending changes to the sample size is a positive signal, suggesting no significant safety concerns or lack of efficacy were identified at this stage. For a clinical-stage biopharmaceutical company, successful progression through trials is paramount, especially given the company's recent financial performance. This update de-risks the program somewhat and maintains the timeline for topline data in mid-2026, which will be a significant catalyst for the stock.